Pliant Therapeutics (PLRX) Long-Term Debt Issuances (2022 - 2024)

Pliant Therapeutics (PLRX) reported Long-Term Debt Issuances of $1000.0 for Q4 2024, down 99.99% quarter-over-quarter from $19.9 million in Q1 2024.

Pliant Therapeutics (PLRX) Long-Term Debt Issuances (2022 - 2024) Analysis & Trends

Pliant Therapeutics (PLRX) has 2 years of Long-Term Debt Issuances data on file, last reported at $1000.0 in Q4 2024.

Long-Term Debt Issuances for Q4 2024 came in at $1000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $1000.0 (down 99.99% YoY), and the FY2024 annual result was $19.9 million, changed N/A from the prior year.
Long-Term Debt Issuances declined to $1000.0 in Q4 2024 per PLRX's latest filing, from $19.9 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $19.9 million in Q1 2024 and troughed at -$150000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	LT Debt Issuance (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	2.73 Mn
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	-
9	Abivax	94.37 Bn	94.37 Bn	-	-
10	Pliant Therapeutics	71.07 Mn	71.07 Mn	-	-

Download Data